FOGHORN THERAPEUTICS INC. (FHTX) - FOGHORN THERAPEUTICS INC

Financial Performance:

• Cash runway extended into the second half of 2029 following a restructuring completed in early October.
• Capital allocation prioritizes funding the EP300 program to IND status, INI program non-GLP/GLP toxicology, and CBP in vivo pharmacology.
• No specific revenue, profit, or debt figures provided as the company remains in the pre-commercial clinical stage.

Guidance and Future Outlook:

• EP300 Program: Targeting Investigational New Drug (IND) filing by end of 2027; potential partnership or financing to fund clinical initiation.
• INI Program (IBD): Non-GLP toxicology studies scheduled for December; aiming for First-in-Human (FIH) studies before end of 2027; goal to reach SADMAD and potential disease patient data by Q3 2028.
• Induced Proximity Platform: Expecting in vitro proof-of-concept data disclosure in the first half of next year; potential business development activity targeted for 2027.
• CBP Program: Go/No-Go decision expected in the first half of next year following completion of in vivo pharmacology and human dose projection modeling.
• Long-term Strategy: Moving beyond chromatin remodeling and synthetic lethality to target protein dependencies, secreted cytokines, and transmembrane proteins via induced proximity.

Business Segments and Product Lines:

• FHD-909 (SMARCA2): Program discontinued in collaboration with Eli Lilly due to lack of clinical efficacy despite preclinical promise; management views the biology (synthetic lethality in this context) as flawed rather than a molecule failure.
• EP300 Program: Focused on hematological malignancies (Multiple Myeloma, DLBCL); once-a-week subcutaneous formulation; high selectivity (100x–10,000x over CBP) intended to reduce thrombocytopenia compared to dual CBP/EP300 inhibitors; data from partner Cellcentric (Obradib) viewed as supportive.
• CBP Program: Targeting ER-positive breast cancer; delayed due to a CRO's animal facility loss in August; currently redone in vivo modeling; formulation is a once-a-week long-acting injectable.
• INI Program: Novel program targeting inflammatory bowel disease (Ulcerative Colitis and Crohn's); highly selective chemical matter; preclinical efficacy comparable to anti-IL-12/23P40 antibodies in murine models; potential expansion to psoriasis.
• Induced Proximity Platform: Leveraging ER biology to degrade secreted cytokines (e.g., IL-12, IL-23, TNF-alpha) and transmembrane proteins; early-stage screening for molecular glues and binders.

Market and Competitive Landscape:

• Myeloma: Acknowledges established mechanisms (CD38, BCMA, IMiDs, Proteasome inhibitors) and high relapse rates; sees opportunity in second-to-fourth line settings with an orthogonal mechanism that avoids cumulative cytopenias.
• Target Validation: Notes Cellcentric's dual CBP/EP300 program validates the target class; Foghorn aims to offer a differentiated, more selective approach.
• Competitive Moat: Claims INI target in IBD is unique with no public competitors identified; platform capabilities in degrading difficult-to-drug proteins and complexes are central to their value proposition.
• Strategic Positioning: Management indicates openness to partnering for oncology programs (breast, lung, prostate, myeloma) to manage complex combination regimens, potentially before clinical trials.

Risks and Challenges:

• Clinical Risk: Recent discontinuation of FHD-909 highlights the risk that preclinical synthetic lethality biology may not translate clinically; management expresses skepticism regarding similar degrader/inhibitor approaches on SMARCA2.
• Operational Delays: CBP program delayed due to external CRO failure (animal facility loss), requiring re-work of in vivo models.
• Biomarker Uncertainty: No specific biomarkers currently identified for patient selection in Multiple Myeloma for the EP300 program.
• Target Safety: Risk of thrombocytopenia associated with dual CBP/EP300 inhibition; Foghorn's strategy relies on selectivity to mitigate this.
• Capital Efficiency: Reliance on existing cash runway; potential need for financing or partnerships to fund large oncology trials.

Management Commentary and Tone:

• Tone: Realistic and pragmatic regarding the FHD-909 failure; confident in the evolution of the platform and the specificity of new programs.
• Confidence: High confidence in the EP300 and INI programs' timelines and preclinical data; open to strategic partnerships but emphasizes value creation.
• Strategic Shift: Clearly articulated pivot from chromatin remodeling to broader protein dependency and secreted protein degradation to maximize platform utility.

Analyst Questions and Answers:

• Q: SMARCA2 Target Validation: Management stated the target itself may be valid but the specific synthetic lethality approach was flawed; expressed skepticism for other industry players pursuing similar strategies.
• Q: EP300 Differentiation: Explained that their degrader achieves >100x selectivity over CBP, potentially eliminating the thrombocytopenia seen with dual inhibitors like Cellcentric's.
• Q: CBP Program Timeline: Confirmed delay due to CRO facility loss; now focused on completing in vivo pharmacology to establish human dose projections for a Go/No-Go decision.
• Q: INI Program Details: Disclosed specific preclinical models (T-cell transfer colitis, IL-10 knockout) and data comparing favorably to existing biologics; confirmed toxicology schedule.
• Q: Future Catalysts: Management outlined key milestones for the next 12–24 months including IND filing (EP300), toxicology results (INI), and proof-of-concept for the induced proximity platform.

Other Key Points:

• The company is no longer targeting the BAF complex or synthetic lethality, having moved to the second "chapter" of the company focused on clear oncology dependencies and novel biology.
• The induced proximity platform is considered early-stage but represents a significant "open" area for partnership and potential molecular glue discovery.
• Management emphasized that the FHD-909 decision was a collaborative effort with Lilly and reflects a strategic course correction rather than a failure of execution.